Rapport Therapeutics (RAPP) Other Accumulated Expenses (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Other Accumulated Expenses data on file, last reported at $144000.0 in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $144000.0, down 55.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $144000.0 (down 55.56% YoY), and the FY2025 annual result was $6000.0, down 98.72% from the prior year.
• Other Accumulated Expenses climbed to $144000.0 in Q1 2026 per RAPP's latest filing, from $6000.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $469000.0 in Q4 2024 and troughed at $6000.0 in Q4 2025.
• A 4-year average of $208666.7 and a median of $144000.0 in 2026 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses surged 311.4% in 2024, then slumped 98.72% in 2025.
• A 4-year view of Other Accumulated Expenses shows it stood at $114000.0 in 2023, then jumped by 311.4% to $469000.0 in 2024, then tumbled by 98.72% to $6000.0 in 2025, then surged by 2300.0% to $144000.0 in 2026.
• Business Quant data shows RAPP's Other Accumulated Expenses at $144000.0 in Q1 2026, $6000.0 in Q4 2025, and $104000.0 in Q3 2025.